Current Status of Screening for Malignant Pleural Mesothelioma

Seminars in Thoracic and Cardiovascular Surgery

Volumn 21, Issue 2, 2009, Pages 97-104

  Pass, Harvey I ^a   Carbone, Michele ^b  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF HAWAII   (United States)

Author keywords

biomarkers; computerized tomography; mesothelioma; screening

Indexed keywords

ASBESTOS; BIOLOGICAL MARKER; MEGAKARYOCYTE POTENTIATING FACTOR; MESOTHELIN; OSTEOPONTIN; PROTEIN; SOLUBLE MESOTHELIN RELATED PROTEIN; UNCLASSIFIED DRUG;

ALGORITHM; ARTICLE; CANCER DIAGNOSIS; CANCER SCREENING; CANCER STAGING; CANCER THERAPY; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; EARLY DIAGNOSIS; HIGH RISK PATIENT; HUMAN; HYPOTHESIS; MALIGNANT MESOTHELIOMA; NON INVASIVE MEASUREMENT; OCCUPATIONAL EXPOSURE; PATIENT MONITORING; PLEURA MESOTHELIOMA; SENSITIVITY AND SPECIFICITY; SURVIVAL TIME; THORAX RADIOGRAPHY;

ASBESTOS; GPI-LINKED PROTEINS; HUMANS; MASS SCREENING; MEMBRANE GLYCOPROTEINS; MESOTHELIOMA; OCCUPATIONAL EXPOSURE; OSTEOPONTIN; PATIENT SELECTION; PLEURAL NEOPLASMS; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL;

EID: 70349748532     PISSN: 10430679     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semtcvs.2009.06.007     Document Type: Article

References (70)

1. Carroll S., Hensler D., Abrahamse A., et al. Asbestos litigation costs and compensation: An interim report (2002), Rank Organisation publications Report No.: ISBN:0-8330-3294. DB-397-ICJ
2. Shah N., and Williams A. Surviving the asbestos epidemic. Insur Digest (Eur) 15 (2001) 14-18
3. Leigh J: Asbestos-related diseases: International estimates of future liability. Proc Int Cong Work Injuries Prev, Rehab, Compensation (Workcongress5); Adelaide, 2001, p. 102
4. Wagner J.C., Sleggs C.A., and Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med 17 (1960) 260-271
5. Roggli V.L., Sharma A., Butnor K.J., et al. MM and occupational exposure to asbestos: A clinicopathological correlation of 1445 cases. Ultrastruct Pathol 26 (2002) 55-65
6. Schottenfeld D., and Fraumeni J.F. Cancer Epidemiology and Prevention (1982), WB Saunders, Philadelphia, PA
7. U.S. Department of Labor OSaHA. Safety and Health Topics: Asbestos (2003) [Internet Communication]
8. Selikoff I.J., Hammond E.C., and Seidman H. Latency of asbestos disease among insulation workers in the United States and Canada. Cancer 46 (1980) 2736-2740
9. National Academy of Sciences. Asbestiform Fibers: Non-Occupational Health Risks (1984), National Academies Press, Washington, DC
10. Mossman B.T., Bignon J., Corn M., et al. Scientific developments and implications for public policy. Science 247 (1990) 294-301
11. Lange J.H. Cough and bronchial responsiveness in firefighters at the World Trade Center site. N Engl J Med 348 (2003) 76-77
12. Lioy P.J., Weisel C.P., Millette J.R., et al. Characterization of the dust/smoke aerosol that settled east of the World Trade Center (WTC) in lower Manhattan after the collapse of the WTC 11 September 2001. Environ Health Perspect 110 (2002) 703-714
13. Wallingford K.M., and Snyder E.M. Occupational exposures during the World Trade Center disaster response. Toxicol Ind Health 17 5-10 (2001) 247-253
14. Dodson R.F., Williams M.G., and Satterley J.D. Asbestos burden in two cases of mesothelioma where the work history included manufacturing of cigarette filters. J Toxicol Environ Health A 65 (2002) 1109-1120
15. Harries P.G., Mackenzie F.A., Sheers G., et al. Radiological survey of men exposed to asbestos in naval dockyards. Br J Ind Med 29 (1972) 274-279
16. Koskinen K., Rinne J.P., Zitting A., et al. Screening for asbestos-induced diseases in Finland. Am J Ind Med 30 (1996) 241-251
17. Karjalainen A., Pukkala E., Kauppinen T., et al. Incidence of cancer among Finnish patients with asbestos-related pulmonary or pleural fibrosis. Cancer Causes Control 10 (1999) 51-57
18. Barnhart S., Keogh J., Cullen M.R., et al. The CARET asbestos-exposed cohort: Baseline characteristics and comparison to other asbestos-exposed cohorts. Am J Ind Med 32 (1997) 573-581
19. Omenn G.S., Goodman G., Thornquist M., et al. The beta-carotene and retinol efficacy trial (CARET) for chemoprevention of lung cancer in high risk populations: Smokers and asbestos-exposed workers. Cancer Res 54 suppl (1994) 2038s-2043s
20. Henschke C.I., McCauley D.I., Yankelevitz D.F., et al. Early lung cancer action project: Overall design and findings from baseline screening. Lancet 354 (1999) 99-105
21. Tiitola M., Kivisaari L., Huuskonen M.S., et al. Computed tomography screening for lung cancer in asbestos-exposed workers. Lung Cancer 35 (2002) 17-22
22. Vierikko T., Jarvenpaa R., Autti T., et al. Chest CT screening of asbestos-exposed workers: Lung lesions and incidental findings. Eur Respir J 29 (2007) 78-84
23. Fasola G., Belvedere O., Aita M., et al. Low-dose computed tomography screening for lung cancer and pleural mesothelioma in an asbestos-exposed population: Baseline results of a prospective, nonrandomized feasibility trial-An Alpe-adria Thoracic Oncology Multidisciplinary Group Study (ATOM 002). Oncologist 12 (2007) 1215-1224
24. Das M., Muhlenbruch G., Mahnken A.H., et al. Asbestos Surveillance Program Aachen (ASPA): Initial results from baseline screening for lung cancer in asbestos-exposed high-risk individuals using low-dose multidetector-row CT. Eur Radiol 17 (2007) 1193-1199
25. Roberts H.C., Patsios D.A., Paul N.S., et al. Screening for malignant pleural mesothelioma and lung cancer in individuals with a history of asbestos exposure. J Thorac Oncol (2009) (in press)
26. Egedahl R.D., Olsen G.W., Coppock E., et al. An historical prospective mortality study of the Sarnia Division of Dow Chemical Canada Inc., Sarnia, Ontario (1950-1984). Can J Pub Health 80 6 (1989) 441-446
27. Robinson M., and Wiggins J. Statement on MM in the UK. Thorax 57 (2002) 187
28. Scherpereel A. Guidelines of the French Speaking Society for chest medicine for management of malignant pleural mesothelioma. Respir Med 101 6 (2006) 1265-1276
29. Ebert W., Hoppe M., Muley T., et al. Monitoring of therapy in inoperable lung cancer patients by measurement of CYFRA 21-1, TPA-TP Cea, and NSE. Anticancer Res 17 (1997) 2875-2878
30. Pettersson T., Fröseth B., Riska H., et al. Concentration of hyaluronic acid in pleural fluid as a diagnostic aid for MM. Chest 94 (1988) 1037-1039
31. Frebourg T., Lerebours G., Delpech B., et al. Serum hyaluronate in malignant pleural mesothelioma. Cancer 59 (1987) 2104-2107
32. Roboz J., Greaves J., Silides D., et al. Hyaluronic acid content of effusions as a diagnostic aid for MM. Cancer Res 45 (1985) 1850-1854
33. Chiu B., Churg A., Tengblad A., et al. Analysis of hyaluronic acid in the diagnosis of MM. Cancer 54 (1984) 2195-2199
34. Boersma A., Degand P., and Biserte G. Hyaluronic acid analysis and the diagnosis of pleural mesothelioma. Bull Physiol Pathol Respir (Nancy) 16 (1980) 41-45
35. Hellstrom P.E., Friman C., and Teppo L. Of 17 years' duration with high pleural fluid concentration of hyaluronate. Scand J Respir Dis 58 (1977) 97-102
36. Thylen A., Wallin J., and Martensson G. Hyaluronan in serum as an indicator of progressive disease in hyaluronan-producing MM. Cancer 86 (1999) 2000-2005
37. Pluygers E., Baldewyns P., Minette P., et al. Biomarker assessments in asbestos-exposed workers as indicators for selective prevention of mesothelioma or bronchogenic carcinoma: Rationale and practical implementations. Eur J Cancer Prev 1 2 (1992) 129-138
38. Hedman M., Arnberg H., Wernlund J., et al. Tissue polypeptide antigen (TPA), hyaluronan and ca 125 as serum markers in MM. Anticancer Res 23 (2003) 531-536
39. Paganuzzi M., Onetto M., Marroni P., et al. Diagnostic value of CYFRA 21-1 tumor marker and CEA in pleural effusion due to mesothelioma. Chest 119 (2001) 1138-1142
40. Lee Y.C., Knox B.S., and Garrett J.E. Use of cytokeratin fragments 19.1 and 19.21 (Cyfra 21-1) in the differentiation of malignant and benign pleural effusions. Aust NZ J Med 29 (1999) 765-769
41. Schouwink H., Korse C.M., Bonfrer J.M., et al. Prognostic value of the serum tumour markers Cyfra 21-1 and tissue polypeptide antigen in MM. Lung Cancer 25 (1999) 25-32
42. Marukawa M., Hiyama J., Shiota Y., et al. The usefulness of CYFRA 21-1 in diagnosing and monitoring malignant pleural mesothelioma. Acta Med Okayama 52 (1998) 119-123
43. Cremades M.J., Menendez R., Pastor A., et al. Diagnostic value of cytokeratin fragment 19 (CYFRA 21-1) in bronchoalveolar lavage fluid in lung cancer. Respir Med 92 (1998) 766-771
44. Bonfrer J.M., Schouwink J.H., Korse C.M., et al. 21-1 And TPA as markers in MM. Anticancer Res 17 (1997) 2971-2973
45. Almudevar B.E., Garcia-Rostan Perez G.M., Garcia B.F., et al. Prognostic value of high serum levels of ca-125 in malignant secretory peritoneal mesotheliomas affecting young women. A case report with differential diagnosis and review of the literature. Histopathology 31 (1997) 267-273
46. Chang K., Pai L.H., Pass H., et al. Monoclonal antibody K1 reacts with epithelial mesothelioma but not with lung adenocarcinoma. Am J Surg Pathol 16 (1992) 259-268
47. Brinkmann U., Webber K., Di Carlo A., et al. Cloning and expression of the recombinant FAb fragment of monoclonal antibody K1 that reacts with mesothelin present on mesotheliomas and ovarian cancers. Int J Cancer 71 (1997) 638-644
48. Ordonez N.G. Value of mesothelin immunostaining in the diagnosis of mesothelioma. Mod Pathol 16 (2003) 192-197
49. Ordonez N.G. Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol 27 (2003) 1418-1428
50. Hassan R., Remaley A.T., Sampson M.L., et al. Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin Cancer Res 12 (2006) 447-453
51. Wali A., Morin P.J., Hough C.D., et al. Identification of intelectin overexpression in malignant pleural mesothelioma by serial analysis of gene expression (SAGE). Lung Cancer 48 (2005) 19-29
52. Onda M., Nagata S., Ho M., et al. Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesothelioma. Clin Cancer Res 12 (2006) 4225-4231
53. Scherpereel A., Grigoriu B., Conti M., et al. Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med 173 (2006) 1155-1160
54. Scholler N., Fu N., Yang Y., et al. Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc Natl Acad Sci USA 96 (1999) 11531-11536
55. Robinson B.W., Creaney J., Lake R., et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 362 (2003) 1612-1616
56. Creaney J., Yeoman D., Demelker Y., et al. Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with MM. J Thorac Oncol 3 (2008) 851-857
57. Park E.K., Sandrini A., Yates D.H., et al. Soluble mesothelin-related protein in an asbestos-exposed population: The dust diseases board cohort study. Am J Respir Crit Care Med 178 (2008) 832-837
58. Creaney J., van Bruggen I., Hof M., et al. Combined CA125 and mesothelin levels for the diagnosis of MM. Chest 132 (2007) 1239-1246
59. Robinson B.W., Creaney J., Lake R., et al. Soluble mesothelin-related protein-A blood test for mesothelioma. Lung Cancer 49 suppl 1 (2005) S109-S111
60. Portal J.R., Becerra E.R., Rodriguez D.R., et al. Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: Relation with past asbestos exposure. Cancer Epidemiol Biomarkers Prev 18 (2009) 646-650
61. Pass H.I., Wali A., Tang N., et al. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions. Ann Thorac Surg 85 (2008) 265-272
62. Creaney J., Yeoman D., Naumoff L., et al. Soluble mesothelin in effusions-A useful tool for the diagnosis of MM. Thorax 62 7 (2007) 569-576
63. Grigoriu B.D., Chahine B., and Scherpereel A. Kinetics of soluble mesothelin in patients with malignant pleural mesothelioma during treatment. Am J Respir Crit Care Med 179 10 (2009) 950-954
64. Ivanov S.V., Ivanova A.V., Goparaju C.M., et al. Tumorigenic properties of alternative osteopontin isoforms in mesothelioma. Biochem Biophys Res Commun 382 (2009) 514-518
65. Sandhu H., Dehnen W., Roller M., et al. mRNA expression patterns in different stages of asbestos-induced carcinogenesis in rats. Carcinogenesis 21 (2000) 1023-1029
66. Pass H.I., Lott D., Lonardo F., et al. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 353 (2005) 1564-1573
67. Park E.K., Thomas P.S., Johnson A.R., et al. Levels in an asbestos-exposed population. Clin Cancer Res 15 (2009) 1362-1366
68. Grigoriu B.D., Scherpereel A., Devos P., et al. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin Cancer Res 13 (2007) 2928-2935
69. Beck A., Ivanova A., and Pass H.I. Evaluation of plasma osteopontin as early detection and prognostic marker in malignant pleural mesothelioma. J Clin Oncol 26 (2008) A11074 (abstract)
70. Carbone M., Emri S., Dogan A.U., et al. A mesothelioma epidemic in Cappadocia: Scientific developments and unexpected social outcomes. Nat Rev Cancer 7 (2007) 147-154